ArticleESMO gastrointestinal oncology2026
Clinician and patient attitudes toward locoregional treatment of oligometastatic oesophago-gastric cancers: a mixed-methods study.
Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of locoregional treatment in oligometastatic oesophago-gastric (OG) cancer remains uncertain, with conflicting trial evidence and limited guidance for clinical practice. This study aimed to evaluate clinician and patient attitudes toward locoregional management, assess clinical equipoise, and explore trade-offs between survival gain and quality of life (QOL) reduction in response to locoregional therapies. Materials and methods: A cross-sectional survey of clinicians involved in multidisciplinary management of OG cancer was conducted between August and December 2025. Scenario-based questions assessed acceptability of combined survival gain (6-15 months) and QOL reduction (5%-20%) as a modified discrete choice experiment. A clustered logistic regression model evaluated the independent effects of survival gain and QOL reduction on clinician acceptability. Patient and public involvement workshops were undertaken to understand patient preferences in potential future trial design. Results: Thirty clinicians from 24 centres participated. Sixty percent reported offering locoregional treatment following stability on systemic therapy. Approximately 93% of respondents indicated willingness to participate in a randomised controlled trial (RCT). Acceptability of treatment strategies increased with greater survival gain and decreased with increasing QOL reduction. In clustered regression analysis, each additional 3 months of survival gain increased the odds of acceptability by ∼75%, whereas each additional 5% QOL reduction decreased the odds by ∼45%. Conclusion: There is substantial variation in clinician attitudes toward locoregional treatment of oligometastatic OG cancer, but marked equipoise and high trial willingness exist. Acceptability is strongly influenced by the balance between survival benefit and QOL impact. These findings support the design of prospective RCTs incorporating patient-centred outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.